Spots Global Cancer Trial Database for Topical Itraconazole in Treating Patients With Basal Cell Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Topical Itraconazole in Treating Patients With Basal Cell Cancer
Official Title: A Case Study of the Effects of Topical Itraconazole on Pharmacodynamic Modulation of Hedgehog Target Gene Expression in Basal Cell Carcinomas in Patients
Study ID: NCT02735356
Conditions
Study Description
Brief Summary: This phase 0 trial studies how well itraconazole gel works in treating patients with basal cell cancer. Itraconazole gel may help to treat basal cell tumors in patients.
Detailed Description: PRIMARY OBJECTIVES: I. To determine if 12 weeks of topical itraconazole gel reduces basal cell carcinoma (BCC) biomarkers (Gli1, the target gene of the Hedgehog pathway). SECONDARY OBJECTIVES: I. To determine if topical itraconazole gel will decrease BCC size. OUTLINE: Patients apply itraconazole topically twice daily (BID) and placebo topically BID for 12 weeks. After completion of study treatment, patients are followed up for up to 14 weeks.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford Cancer Institute, Palo Alto, California, United States
Contact Details
Name: Anthony Oro
Affiliation: Stanford Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
